Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017-Reference-Cited by-同舟云学术

Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017

Published:2020-03-17 Issue:5 Volume:13 Page:557-564
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Durup Darshana¹,Schaffalitzky de Muckadell Philip¹,Strom Claes Christian¹

Affiliation:

1. Pharmacosmos A/S, Medical Affairs, Holbæk, Denmark

Funder

funded by Pharmacosmos A/S

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1738215

Reference51 articles.

1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: a systematic analysis of population-representative data

3. The Global Burden of Anemia

4. Iron deficiency

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia;Blood Advances;2024-05-31

2. Parenteral Iron Therapy for Pediatric Patients;Hemato;2024-01-19

3. Use of iron in perinatal anaemia: Indications for women’s health care policies and procedure;World Journal of Obstetrics and Gynecology;2023-12-28

4. IV iron formulations and use in adults;Hematology;2023-12-08

5. Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons;Diabetology & Metabolic Syndrome;2022-12-23